87 related articles for article (PubMed ID: 11571647)
1. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
3. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
4. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
5. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
6. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
8. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
9. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
10. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.
Morello S; Olivero M; Aimetti M; Bernardi M; Berrone S; Di Renzo MF; Giordano S
J Cell Physiol; 2001 Dec; 189(3):285-90. PubMed ID: 11748586
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.
Matsushita A; Götze T; Korc M
Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973
[TBL] [Abstract][Full Text] [Related]
15. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
Bertotti A; Comoglio PM; Trusolino L
Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
[TBL] [Abstract][Full Text] [Related]
16. The Met tyrosine kinase receptor in development and cancer.
Gentile A; Trusolino L; Comoglio PM
Cancer Metastasis Rev; 2008 Mar; 27(1):85-94. PubMed ID: 18175071
[TBL] [Abstract][Full Text] [Related]
17. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro.
Su W; Gutmann DH; Perry A; Abounader R; Laterra J; Sherman LS
Glia; 2004 Feb; 45(3):297-306. PubMed ID: 14730703
[TBL] [Abstract][Full Text] [Related]
18. Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3.
Cramer A; Kleiner S; Westermann M; Meissner A; Lange A; Friedrich K
J Cell Biochem; 2005 Jul; 95(4):805-16. PubMed ID: 15838885
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
[TBL] [Abstract][Full Text] [Related]
20. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
